Investor Centre

Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce positive results of its recently completed Phase II trial of Bronchitol® (mannitol) in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients, regardless of concomitant dornase alfa use.